Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) is a global leader in innovative eye care solutions, specializing in visioncare products and ophthalmic surgical equipment. This page aggregates official company announcements, financial disclosures, and strategic developments for stakeholders tracking its market position.
Access real-time updates on product innovations, regulatory milestones, and financial performance. Investors and industry professionals will find curated press releases covering earnings reports, partnership announcements, and clinical trial outcomes.
Key content includes updates on contact lens technologies, intraocular lens advancements, and surgical system innovations. All materials are sourced directly from Alcon's communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to Alcon's latest developments. Combine this resource with SEC filings and market analysis tools for comprehensive investment research.
Alcon (NYSE: ALC) announced the launch of TOTAL30®, a revolutionary monthly replacement Water Gradient contact lens. This lens offers unparalleled comfort, feeling like nothing even on day 30. The reusable lens segment represents 45% of the $9 billion global contact lens market. TOTAL30 integrates new CELLIGENT™ Technology, enhancing durability and reducing bacteria adhesion. Set for U.S. release in September 2021, it aims to meet the needs of the two-thirds of contact lens wearers who prefer reusable options, addressing a decade-long innovation gap in this segment.
Alcon (SIX/NYSE: ALC) will present over 60 abstracts at the ASCRS 2021 meeting in Las Vegas, focusing on its ophthalmic products, particularly presbyopia-correcting intraocular lenses (IOLs) like AcrySof® Vivity™ IQ, AcrySof® PanOptix®, and Clareon® IOL. Key findings show Vivity IOL achieves 94% distance vision without glasses and 90% patient satisfaction. Presentations will also cover innovations such as the ARGOS® biometer and NGENUITY® 3D visualization system, demonstrating Alcon's commitment to surgical efficiency and patient outcomes in cataract procedures.
Alcon (SIX/NYSE: ALC) announced key changes to its Executive Committee effective September 1, 2021. Ian Bell is appointed President, Global Business & Innovation, while Michael Onuscheck steps down. Raj Narayanan succeeds Bell as President, International. Sue-Jean Lin becomes Chief Information & Transformation Officer, joining the committee. CEO David Endicott expressed confidence in these leaders to drive innovation and growth post-COVID-19. The Executive Committee will continue with seven members, ensuring effective management and strategic implementation for Alcon’s future.
Alcon (SIX/NYSE: ALC) will showcase new findings at the BCLA 2021 Conference, highlighting its innovative TOTAL30® monthly replacement water gradient contact lens. Cheryl Donnelly, International Head of Professional Affairs, emphasized the lens's focus on comfort and vision to enhance wearer retention. The TOTAL30 lens boasts exceptional lubricity and high durability, with plans for U.S. and European market introduction in 2021, followed by global availability in 2022. Alcon's participation as a sponsor includes virtual sessions and a booth for eye care professionals to explore these innovations.
Alcon, a global leader in eye care, reported Q1 2021 financial results reflecting a 5% increase in worldwide sales to $1.9 billion. Diluted EPS was $0.17, with core diluted EPS at $0.49. Surgical segment sales rose 9%, driven by demand for cataract equipment. Vision Care sales declined 1%, impacted by prior year stocking activity. Operating income reached $149 million, with core operating margin at 18.0%. The company ended the quarter with $1.6 billion in cash and provided a full-year outlook of $7.8 to $8.0 billion in net sales.
Alcon (SIX/NYSE: ALC) has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) from Novartis for $355 million, closing in Q2 2021. This acquisition strengthens Alcon's ophthalmic portfolio, allowing it to tap into the glaucoma market and the growing dry eye segment. Simbrinza, approved by the FDA in 2013, is a combination therapy for elevated intraocular pressure, which is crucial for preventing optic nerve damage. Alcon expects to handle its manufacturing and commercialization post-transition with Novartis.
Alcon Inc. (SIX/NYSE: ALC) held its 2021 Annual General Meeting, where 70.87% of shares were represented. Mike Ball was re-elected as Chair, and all Board members up for re-election were maintained. Shareholders approved a dividend of CHF 0.10 per share, marking Alcon's first dividend. The 2020 Compensation Report was not approved in a consultative vote. Pricewaterhouse Coopers SA was re-elected as auditors. Alcon is set to announce its Q1 2021 earnings on May 4. The company emphasizes ongoing product launches and market share growth despite pandemic challenges.
Alcon (SIX/NYSE: ALC) has launched Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Drops in the U.S. This new eye drop aims to provide extra moisture for sensitive dry eyes, utilizing HydroBoost® Technology for enhanced hydration. The preservative-free segment of artificial tears is rapidly growing, comprising over 40% of the global market. Systane remains the leading artificial tear brand worldwide. The new drops are intended for patients requiring frequent eye relief and will be available at major pharmacies and online retailers in the U.S.
Alcon (NYSE: ALC) will hold its Annual General Meeting (AGM) on April 28, 2021, without in-person attendance due to COVID-19. Shareholders must submit voting instructions to an independent representative. Key agenda items include approval of the 2020 financial statements, dividend declaration of CHF 0.10 per share, re-election of the Board of Directors, and compensation votes for both the Board and Executive Committee. The dividend is subject to a 35% withholding tax. Further details will be available online from March 25, 2021.
Alcon will host a virtual Capital Markets Day on March 24, 2021, aimed at investors and the financial community. The event will highlight Alcon's strategy and innovation in eye care, featuring presentations from CEO David Endicott and other key leaders. Attendees can explore a virtual booth showcasing the latest innovations starting at 13:30 CET and watch presentations beginning at 14:00 CET. The event includes live Q&A sessions and registration is open until March 23. For more details, visit the Investor Relations section.
